Table 4.
Multivariate logistic regression modeling the likelihood of receiving medical care for a targeted fungal or mycobacterial infection (n = 614)*
| Estimated OR (95% CI) | P | |
|---|---|---|
| Race | ||
| White vs. other | 0.89 (0.57–1.40) | 0.61 |
| Education | 0.19 | |
| Some college vs. high school or less | 1.31 (0.87–1.95) | |
| Region | ||
| Midwest vs. South | 0.86 (0.53–1.41) | 0.56 |
| Northeast vs. South | 1.17 (0.64–2.14) | 0.62 |
| West vs. South | 1.77 (1.05–2.98) | 0.032 |
| TNF inhibitor prescribed | ||
| Adalimumab vs. etanercept | 1.05 (0.69–1.62) | 0.81 |
| Infliximab vs. etanercept | 1.08 (0.66–1.77) | 0.77 |
| Certolizumab vs. etanercept | 0.78 (0.07–8.21) | 0.83 |
| Diabetes mellitus | ||
| Yes vs. no | 1.58 (0.96–2.63) | 0.075 |
| Prescribed prednisone | ||
| Yes vs. no | 2.03 (1.37–3.00) | <0.001 |
| Prescribed other medication conferring high risk of infection | ||
| Yes vs. no | 1.02 (0.69–1.52) | 0.92 |
| Prescribed trimethoprim/sulfamethoxazole | ||
| Yes vs. no | 1.45 (0.77–2.71) | 0.25 |
| Pre-drug screening test | ||
| Yes vs. no | 1.08 (0.74–1.59) | 0.69 |
*
A total of 18 patients were omitted due to having missing data for ≥1 variable in the model. OR = odds ratio; 95% CI = 95% confidence interval; TNF = tumor necrosis factor.